-Advertisement-
-Advertisement-
Gastroenterology

Upadacitinib shows promise as maintenance therapy for active ulcerative colitis
Upadacitinib, an oral JAK inhibitor, has shown significant efficacy as a maintenance therapy for patients with moderately to severely active ulcerative colitis, according to a study. The study demonstrated that both maintenance doses of upadacitinib led to a higher proportion of patients achieving clinical remission compared to placebo. In this...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved